BrainStorm

Company Overview

Snapshot

Founded in January 2000, BrainStorm operates with 11–50 employees. The company has raised a total of $67.13M across 17 funding rounds from 3 investors. BrainStorm became public on NASDAQ in October 2003.

Business overview

BrainStorm Cell Therapeutics is a biotechnology company focused on developing autologous stem cell therapeutics for neurodegenerative diseases, specifically amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Its core technology, NurOwn®, transforms mesenchymal stem cells into neurotrophic factor-secreting cells to deliver growth factors to affected areas. The company serves the healthcare and life sciences sectors, targeting patients and providers in the pharmaceutical and biotechnology industries.

Strategic signal

In October 2023, BrainStorm Cell Therapeutics announced a strategic realignment to prioritize NurOwn® for the treatment of ALS. This decision, following an FDA advisory committee meeting that voted against recommending approval for NurOwn®, indicates a focused effort to refine its clinical and regulatory strategy for its lead therapeutic candidate, signaling a critical pivot in its development pathway.

Company Intelligence Q&A

What was the outcome of the FDA advisory committee meeting regarding NurOwn® for ALS?

In September 2023, FDA advisers voted against the experimental ALS treatment NurOwn®, as reported by finance.yahoo.com.

What was the key announcement from BrainStorm Cell Therapeutics in October 2023?

In October 2023, BrainStorm Cell Therapeutics announced a strategic realignment to prioritize NurOwn® for the treatment of ALS, following discussions with the US FDA regarding its development plan.

Did BrainStorm Cell Therapeutics regain compliance with Nasdaq listing requirements?

In October 2024, BrainStorm Cell Therapeutics regained compliance with the Nasdaq minimum bid price requirement.

What was the nature of the funding received in March 2020?

In March 2020, BrainStorm Cell Therapeutics raised capital from ABBHI INVESTMENTS, LLC through a common stock sale.

What was the focus of BrainStorm's presentations at the 2024 Annual NEALS Meeting?

In October 2024, BrainStorm Cell Therapeutics presented positive survival data from its NurOwn® Expanded Access Program at the 2024 Annual NEALS Meeting, and also announced presentations on NurOwn® at the event in September 2024.